NasdaqGM - Nasdaq Real Time Price • USD
Sensei Biotherapeutics, Inc. (SNSE)
At close: May 28 at 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 4 | 3 |
| Avg. Estimate | -0.27 | -0.26 | -1.09 | -1.1 |
| Low Estimate | -0.33 | -0.34 | -1.34 | -1.32 |
| High Estimate | -0.16 | -0.18 | -0.79 | -0.91 |
| Year Ago EPS | -0.31 | -0.28 | -1.22 | -1.09 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 3 | 2 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | -0.33 | -0.34 | -0.31 | -0.27 |
| EPS Actual | -0.31 | -0.28 | -0.3 | -0.32 |
| Difference | 0.02 | 0.06 | 0.01 | -0.05 |
| Surprise % | 6.10% | 17.60% | 3.20% | -18.50% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.27 | -0.26 | -1.09 | -1.1 |
| 7 Days Ago | -0.27 | -0.26 | -1.09 | -1.1 |
| 30 Days Ago | -0.24 | -0.25 | -1.01 | -1.05 |
| 60 Days Ago | -0.24 | -0.25 | -1.01 | -1.05 |
| 90 Days Ago | -0.25 | -0.26 | -1.09 | -1.14 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | SNSE | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 12.90% | -- | -- | 7.90% |
| Next Qtr. | 7.10% | -- | -- | 10.20% |
| Current Year | 10.70% | -- | -- | 4.80% |
| Next Year | -0.90% | -- | -- | 12.50% |
| Next 5 Years (per annum) | -- | -- | -- | 11.27% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/24/2024 |
| Reiterates | Stephens & Co.: Overweight to Overweight | 5/24/2024 |
| Initiated | Stephens & Co.: Overweight | 5/14/2024 |
| Initiated | HC Wainwright & Co.: Buy | 12/4/2023 |
| Initiated | Citigroup: Buy | 12/13/2022 |
| Upgrade | Oppenheimer: Perform to Outperform | 10/3/2022 |
Related Tickers
GNLX Genelux Corporation
2.7900
+6.49%
KRON Kronos Bio, Inc.
0.7548
-0.12%
BCAB BioAtla, Inc.
1.6800
-1.75%
BOLT Bolt Biotherapeutics, Inc.
0.7608
-3.70%
CTMX CytomX Therapeutics, Inc.
1.7900
+2.29%
THAR Tharimmune, Inc.
4.5699
-0.11%
ELEV Elevation Oncology, Inc.
3.8300
-0.26%
ACHL Achilles Therapeutics plc
0.9200
+1.10%
ALGS Aligos Therapeutics, Inc.
0.6130
+5.69%
LYRA Lyra Therapeutics, Inc.
0.3335
+2.46%